The shares of the pharmaceutical company have gained significant attention following the announcement of its acquisition deal.
This strategic move involves acquiring the remaining 12% stake in its biologics subsidiary, which is expected to strengthen its position in the biotechnology market.
The acquisition is valued at Rs. 231.87 crore, reflecting the company's commitment to expanding its operations and enhancing its product offerings.